Investigating the Effect of Type II Diabetes on COVID-19 Pneumonia Severity Using Computed Tomography: A Comparative Analysis
Creators
- 1. Department of Radiology, Ahi Evran University Faculty of Medicine, Kırşehir, Türkiye.
Description
Abstract
The aim of this study was to determine the factors affecting the severity of COVID-19 pneumonia in patients with type 2 diabetes using computed tomography severity scores. Computed tomography findings and pneumonia scores of 136 patients with type 2 diabetes and 136 patients without diabetes (n=272) with positive polymerase chain reaction test between January 2020 and January 2021 were compared using the hospital information system. The number of patients with moderate and severe pneumonia was significantly higher in the type 2 diabetes group (p<0.05). Pneumonia scores were significantly higher in type 2 diabetic patients older than 60 years (p<0.05). No significant correlation was found between pneumonia scores and hemoglobin A1c (p=0.865) and fasting blood glucose (p=0.78). No negative effect of hypertension on pneumonia score was observed in diabetic patients. Pneumonia scores of diabetic patients with renal insufficiency were higher than those of diabetic patients aged <60 years (P<0.05). In conclusion, the present study results revealed that the severity of COVID-19 pneumonia in patients with type 2 diabetes is higher than in healthy subjects. However, there was no significant positive correlation between pneumonia severity, hyperglycemia, and hemoglobin A1c levels in patients with type 2 diabetes.
Özet
Bu çalışmanın amacı tip 2 diyabetli hastalarda bilgisayarlı tomografi skorlarını kullanarak COVID-19 pnömonisinin şiddetini etkileyen faktörleri belirlemektir. Ocak 2020 ile Ocak 2021 tarihleri arasında polimeraz zincir reaksiyon testi pozitif olan 136 tip 2 diyabet hastası ile diyabeti olmayan 136 hastanın (n=272) bilgisayarlı tomografi bulguları ve pnömoni skorları hastane bilgi sistemi kullanılarak karşılaştırıldı. Tip 2 diyabet grubunda orta ve şiddetli pnömoni geçiren hasta sayısı anlamlı olarak daha fazlaydı (p<0.05). 60 yaş üstü tip 2 diyabetik hastalarda pnömoni skorları anlamlı olarak daha yüksek bulundu (p<0.05). Pnömoni skorları ile hemoglobin A1c (p=0.865) ve açlık kan şekeri (p=0.78) arasında ise anlamlı bir korelasyon bulunamadı. Diyabetik hastalarda hipertansiyonun pnömoni skoru üzerine olumsuz etkisi gözlenmedi. Böbrek yetmezliği olan diyabetik hastaların pnömoni skorları <60 yaş diyabetik hastalara göre daha yüksekti (P<0.05). Sonuç olarak çalışma verileri tip 2 diyabetli hastalarda COVID-19 pnömonisinin şiddetinin sağlıklı kişilere göre daha yüksek olduğunu göstermektedir. Tip 2 diyabetli hastalarda pnömoni şiddeti ile hiperglisemi ve hemoglobin A1c düzeyleri arasında ise anlamlı bir pozitif korelasyon saptanmamıştır.
Notes
Tip II Diyabetin COVID-19 Pnömoni Şiddeti Üzerindeki Etkisinin Bilgisayarlı Tomografi Kullanılarak Araştırılması: Karşılaştırmalı Bir Analiz
Files
jmvi.2024.84.pdf
Files
(314.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:8f8b9fd6ef776aaafad0cdd2c4510162
|
314.6 kB | Preview Download |
Additional details
References
- 1. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health 2020; 13(12): 1833-9.
- 2. Siddiqi Z, Fatima J, Bhatt D, Shukla V, Malik M, Ashfaq A, et al. Prevalence of Comorbidities in Survivors and Non-Survivors of Severe COVID-19 at a Dedicated COVID Care Centre. J Assoc Physicians India 2022; 70(1): 11-12.
- 3. Yin T, Li Y, Ying Y, Luo Z. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis 2021; 21(1): 200.
- 4. Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One 2021; 16(10): e0258154.
- 5. Michalakis K, Ilias I. COVID-19 and hyperglycemia/diabetes. World J Diabetes 2021; 12(5): 642-50.
- 6. Zhou J, Tan J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism 2020; 107: 154216.
- 7. Wei X, Zhao W, Wang A, Xu Z. Timely glucose monitoring-related potential risk of occupational exposure during the pandemic of COVID-19: A diabetologist's perspective. Diabetes Res Clin Pract 2020; 165: 108196.
- 8. Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev 2021; 65: 101205.
- 9. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020; 295(3): 715-21.
- 10. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19. Radiol Cardiothorac Imaging 2020; 2(2): e200047.
- 11. O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021; 590(7844): 140-5.
- 12. Sahu G, Joshi SH, Mendiratta S. Correlation Between Chest CT Severity Scores and Glycosylated Haemoglobin Levels and its Outcome in Patients With COVID-19: A Retrospective Study in a Tertiary Care Hospital. Cureus 2022; 14(8): e28371.
- 13. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al, Gourdy P; CORONADO investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020; 63(8): 1500-15.
- 14. Raoufi M, Khalili S, Mansouri M, Mahdavi A, Khalili N. Well-controlled vs poorly-controlled diabetes in patients with COVID-19: Are there any differences in outcomes and imaging findings? Diabetes Res Clin Pract 2020; 166: 108286.
- 15. Shu CJ, Benoist C, Mathis D. The immune system's involvement in obesity-driven type 2 diabetes. Semin Immunol 2012; 24(6): 436-42.
- 16. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 2021; 40(5): 905-19.
- 17. Abrishami A, Khalili N, Dalili N, Khaleghnejad Tabari R, Farjad R, Samavat S, et al. Clinical and Radiologic Characteristics of COVID-19 in Patients With CKD. Iran J Kidney Dis 2020; 14(4): 267-77.
- 18. Jdiaa SS, Mansour R, El Alayli A, Gautam A, Thomas P, Mustafa RA. COVID-19 and chronic kidney disease: an updated overview of reviews. J Nephrol 2022; 35(1): 69-85.
- 19. Gallo G, Calvez V, Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press Cardiovasc Prev 2022; 29(2): 115-23.